* within 14 days before vaccination, subjects have been abroad and to villages/communities experienced covid-19 epidemics, and in contact with covid-19 cases or suspected cases. subjects are under isolation observation, or living in the villages/communities with covid-19 cases or suspected cases; * confirmed cases, suspected cases or asymptomatic cases with covid-19 (refer to information system of china disease prevention and control); * subjects with history of sars virus infection by self-reported; * positive in throat swab through rt-pcr; * history of vaccination of various covid-19 vaccines or positive in sars-cov-2 antibody test; * positive urine pregnancy test for females with menarche * with abnormal indicators, such as blood biochemistry, blood routine, urine routine, thyroid function and coagulation function which might show clinical meaning, before administration; * history of severe allergic reactions (such as acute anaphylaxis, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain) or allergy to known composition of inactivated sars-cov-2 vaccine; * history or family history of convulsion, epilepsy, encephalopathy or mental illness; * subjects with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; * subjects with known or suspected diseases include: severe respiratory diseases, severe cardiovascular diseases, severe liver and kidney diseases, drug-uncontrollable hypertension, diabetic complications, malignant tumors, various acute diseases or acute onset of chronic diseases; * diagnosed with congenital or acquired immunodeficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases; * history of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease); * subjects receiving anti-tb treatment; * subjects receiving other research drugs within 6 months before vaccination; * subjects receiving immunotherapy or inhibitor therapy within 3 months (consistently oral or infusion for more than 14 days); * subjects receiving blood products within 3 months before administration; * subjects vaccinated with live attenuated vaccine within 14 days before vaccination; * subjects vaccinated with other vaccine within 7 days before vaccination; * the researchers shall judge the other conditions which might be not in compliance with the requirements of this clinical trial.

* within 14 days before vaccination, subjects have been abroad and to villages/communities experienced covid-19 epidemics, and in contact with covid-19 cases or suspected cases. subjects are under isolation observation, or living in the villages/communities with covid-19 cases or suspected cases; * confirmed cases, suspected cases or asymptomatic cases with covid-19 (refer to information system of china disease prevention and control); * subjects with history of sars virus infection by self-reported; * positive in throat swab through rt-pcr; * history of vaccination of various covid-19 vaccines or positive in sars-cov-2 antibody test; * positive urine pregnancy test for females with menarche * with abnormal indicators, such as blood biochemistry, blood routine, urine routine, thyroid function and coagulation function which might show clinical meaning, before administration; * history of severe allergic reactions (such as acute anaphylaxis, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain) or allergy to known composition of inactivated sars-cov-2 vaccine; * history or family history of convulsion, epilepsy, encephalopathy or mental illness; * subjects with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; * subjects with known or suspected diseases include: severe respiratory diseases, severe cardiovascular diseases, severe liver and kidney diseases, drug-uncontrollable hypertension, diabetic complications, malignant tumors, various acute diseases or acute onset of chronic diseases; * diagnosed with congenital or acquired immunodeficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases; * history of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease); * subjects receiving anti-tb treatment; * subjects receiving other research drugs within 6 months before vaccination; * subjects receiving immunotherapy or inhibitor therapy within 3 months (consistently oral or infusion for more than 14 days); * subjects receiving blood products within 3 months before administration; * subjects vaccinated with live attenuated vaccine within 14 days before vaccination; * subjects vaccinated with other vaccine within 7 days before vaccination; * the researchers shall judge the other conditions which might be not in compliance with the requirements of this clinical trial.

- within 14 days before vaccination, subjects have been abroad and to villages/communities experienced covid-19 epidemics, and in contact with covid-19 cases or suspected cases. subjects are under isolation observation, or living in the villages/communities with covid-19 cases or suspected cases; - confirmed cases, suspected cases or asymptomatic cases with covid-19 (refer to information system of china disease prevention and control); - subjects with history of sars virus infection by self-reported; - positive in throat swab through rt-pcr; - history of vaccination of various covid-19 vaccines or positive in sars-cov-2 antibody test; - positive urine pregnancy test for females with menarche - with abnormal indicators, such as blood biochemistry, blood routine, urine routine, thyroid function and coagulation function which might show clinical meaning, before administration; - history of severe allergic reactions (such as acute anaphylaxis, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain) or allergy to known composition of inactivated sars-cov-2 vaccine; - history or family history of convulsion, epilepsy, encephalopathy or mental illness; - subjects with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; - subjects with known or suspected diseases include: severe respiratory diseases, severe cardiovascular diseases, severe liver and kidney diseases, drug-uncontrollable hypertension, diabetic complications, malignant tumors, various acute diseases or acute onset of chronic diseases; - diagnosed with congenital or acquired immunodeficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases; - history of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease); - subjects receiving anti-tb treatment; - subjects receiving other research drugs within 6 months before vaccination; - subjects receiving immunotherapy or inhibitor therapy within 3 months (consistently oral or infusion for more than 14 days); - subjects receiving blood products within 3 months before administration; - subjects vaccinated with live attenuated vaccine within 14 days before vaccination; - subjects vaccinated with other vaccine within 7 days before vaccination; - the researchers shall judge the other conditions which might be not in compliance with the requirements of this clinical trial.

- within 14 days before vaccination, subjects have been abroad and to villages/communities experienced covid-19 epidemics, and in contact with covid-19 cases or suspected cases. subjects are under isolation observation, or living in the villages/communities with covid-19 cases or suspected cases; - confirmed cases, suspected cases or asymptomatic cases with covid-19 (refer to information system of china disease prevention and control); - subjects with history of sars virus infection by self-reported; - positive in throat swab through rt-pcr; - history of vaccination of various covid-19 vaccines or positive in sars-cov-2 antibody test; - positive urine pregnancy test for females with menarche - with abnormal indicators, such as blood biochemistry, blood routine, urine routine, thyroid function and coagulation function which might show clinical meaning, before administration; - history of severe allergic reactions (such as acute anaphylaxis, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain) or allergy to known composition of inactivated sars-cov-2 vaccine; - history or family history of convulsion, epilepsy, encephalopathy or mental illness; - subjects with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; - subjects with known or suspected diseases include: severe respiratory diseases, severe cardiovascular diseases, severe liver and kidney diseases, drug-uncontrollable hypertension, diabetic complications, malignant tumors, various acute diseases or acute onset of chronic diseases; - diagnosed with congenital or acquired immunodeficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases; - history of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease); - subjects receiving anti-tb treatment; - subjects receiving other research drugs within 6 months before vaccination; - subjects receiving immunotherapy or inhibitor therapy within 3 months (consistently oral or infusion for more than 14 days); - subjects receiving blood products within 3 months before administration; - subjects vaccinated with live attenuated vaccine within 14 days before vaccination; - subjects vaccinated with other vaccine within 7 days before vaccination; - the researchers shall judge the other conditions which might be not in compliance with the requirements of this clinical trial.